{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T11:17:05Z","timestamp":1782386225326,"version":"3.54.5"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.ejca.2020.12.007","type":"journal-article","created":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T03:01:54Z","timestamp":1610161314000},"page":"44-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Germline BRCA1\/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy"],"prefix":"10.1016","volume":"145","author":[{"given":"Jenny","family":"Furlanetto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"M\u00f6bus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schneeweiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Rhiem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Tesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens-Uwe","family":"Blohmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"L\u00fcbbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Untch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Salat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Huober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Klare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Schmutzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fergus J.","family":"Couch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4512-2226","authenticated-orcid":false,"given":"Bianca","family":"Lederer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk-Michael","family":"Zahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Bauerfeind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Nekljudova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Hanusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Jackisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Hahnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibylle","family":"Loibl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Fasching","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2020.12.007_bib1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1097-2765(01)00174-5","article-title":"BRCA2 is required for homology-directed repair of chromosomal breaks","volume":"7","author":"Moynahan","year":"2001","journal-title":"Mol Cell"},{"key":"10.1016\/j.ejca.2020.12.007_bib2","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/35077232","article-title":"Genome maintenance mechanisms for preventing cancer","volume":"411","author":"Hoeijmakers","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2020.12.007_bib3","first-page":"61","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2020.12.007_bib4","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s12885-018-4029-y","article-title":"German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC). Prevalence of pathogenic BRCA1\/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history","volume":"18","author":"Engel","year":"2018","journal-title":"BMC Canc"},{"issue":"5","key":"10.1016\/j.ejca.2020.12.007_bib5","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1001\/jamaoncol.2020.0007","article-title":"Germline mutation status and therapy response in high-risk early-stage 2 breast cancer: a secondary analysis of the GeparOcto randomized clinical trial","volume":"1","author":"Pohl-Rescigno","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2020.12.007_bib6","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1093\/annonc\/mdy460","article-title":"Survival analysis of carboplatin added to an anthracycline\/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto","volume":"29","author":"Loibl","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2020.12.007_bib7","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1200\/JCO.2017.77.2285","article-title":"BRCA1\/2 mutations and bevacizumab in the neoadjuvant treatment of breast cancer: response and prognosis results in patients with triple-negative breast cancer from the GeparQuinto study","volume":"36","author":"Fasching","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.12.007_bib8","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.celrep.2016.12.075","article-title":"Distinct Brca1 mutations differentially reduce hematopoietic stem cell function","volume":"18","author":"Mgbemena","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.ejca.2020.12.007_bib9","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.blre.2016.10.002","article-title":"Recent discoveries in the molecular pathogenesis of the inherited bone marrow failure syndrome Fanconi anemia","volume":"31","author":"Mamrak","year":"2017","journal-title":"Blood Rev"},{"key":"10.1016\/j.ejca.2020.12.007_bib10","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1182\/blood-2015-03-635599","article-title":"Brca1 deficiency causes bone marrow failure and spontaneous hematologic malignancies in mice","volume":"127","author":"Vasanthakumar","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2020.12.007_bib11","doi-asserted-by":"crossref","first-page":"5609","DOI":"10.1002\/cam4.2471","article-title":"Hematologic toxicity in BRCA1 and BRCA2 mutation carriers during chemotherapy: a retrospective matched cohort study","volume":"8","author":"West","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2020.12.007_bib12","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s10549-018-05127-2","article-title":"BRCA1\/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients","volume":"174","author":"Friedlaender","year":"2019","journal-title":"Breast Canc Res Treat"},{"key":"10.1016\/j.ejca.2020.12.007_bib13","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/igc.0000000000001144","article-title":"BRCA mutation status is not associated with increased hematologic toxicity among patients undergoing platinum-based chemotherapy for ovarian cancer","volume":"28","author":"Kotsopoulos","year":"2018","journal-title":"Int J Gynecol Canc"},{"key":"10.1016\/j.ejca.2020.12.007_bib14","doi-asserted-by":"crossref","first-page":"7033","DOI":"10.1158\/1078-0432.CCR-06-1246","article-title":"Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom","volume":"12","author":"Shanley","year":"2006","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.ejca.2020.12.007_bib15","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ygyno.2019.04.009","article-title":"Is BRCA mutational status a predictor of platinum-based chemotherapy related hematologic toxicity in high-grade serous ovarian cancer patients?","volume":"154","author":"Tomao","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejca.2020.12.007_bib16","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s10549-016-3777-0","article-title":"Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer","volume":"156","author":"Drooger","year":"2016","journal-title":"Breast Canc Res Treat"},{"key":"10.1016\/j.ejca.2020.12.007_bib17","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1159\/000354834","article-title":"The influence of BRCA1\/BRCA2 mutations on toxicity related to chemotherapy and radiotherapy in early breast cancer patients","volume":"85","author":"Huszno","year":"2013","journal-title":"Oncology"},{"key":"10.1016\/j.ejca.2020.12.007_bib18","doi-asserted-by":"crossref","first-page":"e1471","DOI":"10.1634\/theoncologist.2019-0272","article-title":"Chemotherapy toxicity in BRCA mutation carriers undergoing first-line platinum-based chemotherapy","volume":"24","author":"Weitzner","year":"2019","journal-title":"Oncol"},{"key":"10.1016\/j.ejca.2020.12.007_bib19","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa1111065","article-title":"Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer","volume":"366","author":"von Minckwitz","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.12.007_bib20","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.ejca.2013.02.027","article-title":"Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin\/cyclophosphamide (EC) \u00b1 bevacizumab - results of the randomised GeparQuinto study (GBG 44)","volume":"49","author":"Huober","year":"2013","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2020.12.007_bib21","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(14)70160-3","article-title":"Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial","volume":"15","author":"von Minckwitz","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2020.12.007_bib22","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1001\/jamaoncol.2017.1007","article-title":"Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial","volume":"3","author":"Hahnen","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2020.12.007_bib23","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ejca.2018.10.015","volume":"106","author":"Schneeweiss","year":"2019","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2020.12.007_bib24","unstructured":"https:\/\/www.ago-online.de\/leitlinien-empfehlungen\/leitlinien-empfehlungen\/kommission-mamma assessed 27.08.2020."},{"key":"10.1016\/j.ejca.2020.12.007_bib25","unstructured":"https:\/\/enigmaconsortium.org\/."},{"key":"10.1016\/j.ejca.2020.12.007_bib26","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/S0891-5849(01)00616-5","article-title":"Direct effect of Taxol on free radical formation and mitochondrial permeability transition","volume":"31","author":"Varbiro","year":"2001","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.ejca.2020.12.007_bib27","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1111\/tbj.13922","article-title":"Clinical outcome and toxicity from taxanes in breast cancer patients with BRCA1 and BRCA2 pathogenic germline mutations","volume":"26","author":"Bayraktar","year":"2020","journal-title":"Breast J"},{"key":"10.1016\/j.ejca.2020.12.007_bib28","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3390\/cancers10120506","article-title":"Targeting BRCA deficiency in breast cancer: what are the clinical evidences and the next perspectives?","volume":"10","author":"Nicolas","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2020.12.007_bib29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.2014.57.0572","volume":"33","author":"Sikov","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.12.007_bib30","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1470-2045(18)30111-6","article-title":"Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial","volume":"19","author":"Loibl","year":"2018","journal-title":"Lancet Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920314210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920314210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:29:42Z","timestamp":1760732982000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804920314210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":30,"alternative-id":["S0959804920314210"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.12.007","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Germline BRCA1\/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}